Tumor Suppressor Par-4: Structural Features, Molecular Mechanisms and Function - Image 1

£130.43

Springer Tumor Suppressor Par-4: Structural Features, Molecular Mechanisms and Function

Name: Tumor Suppressor Par-4: Structural Features, Molecular Mechanisms and Function
Brand: Springer
Price: 130.43 GBP
Availability: InStock

Oncology

New to our records — first sighting 22 days ago. We'll learn its rhythm.

22 days of data · current price £130

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 11 days • 11 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 11 days • 1 price levels

Days at Price

Price Analysis

Most common price: £130 (11 days, 100.0%)

Price range: £130 - £130

Price levels: 1 different prices over 11 days

Description

Par-4 is a tumor suppressor protein first discovered and identified in 1993 by Dr. Vivek Rangnekar’s laboratory in prostate cancer cells undergoing apoptosis. Par-4 (later also known as PAWR) is a naturally occurring tumor suppressor. Studies have indicated that Par-4 selectively induces apoptosis in cancer cells while leaving normal, healthy, cells unaffected. Mechanisms contributing to the cancer-selective action of Par-4 have been associated with protein kinase A activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. Par-4 is downregulated, inactivated or mutated in diverse cancers. This first of two volumes will be the first on the market on the topic of Par-4, and will provide the opportunity for researchers to discuss the future direction of studies, broaden the scope of research, and contribute a more complete understanding of the molecule’s structural features, key functional domains, regulation and relevant basic and clinical/translational facets. From the Back Cover Par-4 is a tumor suppressor protein first discovered and identified in 1993 by Dr. Vivek Rangnekar’s laboratory in prostate cancer cells undergoing apoptosis. Par-4 (later also known as PAWR) is a naturally occurring tumor suppressor. Studies have indicated that Par-4 selectively induces apoptosis in cancer cells while leaving normal, healthy, cells unaffected. Mechanisms contributing to the cancer-selective action of Par-4 have been associated with protein kinase A activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. Par-4 is downregulated, inactivated or mutated in diverse cancers. This first of two volumes will be the first on the market on the topic of Par-4, and will provide the opportunity for researchers to discuss the future direction of studies, broaden the scope of research, and contribute a more complete understanding of the molecule’s structural features, key functional domains, regulation and relevant basic and clinical/translational facets. About the Author Vivek M. Rangnekar, Ph.D. is Professor and Alfred Cohen Chair in Oncology Research in the Department of Radiation Medicine and Associate Director of the Markey Cancer Center at the University of Kentucky. His laboratory studies the molecular cross-talk between oncogenes and tumor suppressor genes in an effort to tilt the balance in favor of tumor suppressor function. Dr. Rangnekar originally discovered and identified the tumor suppressor protein Par-4/PAWR in 1993.

Product Specifications

Brand: Springer
Format: hardcover
ASIN: 3030735710
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 09 January 2022
Listed Since: 07 March 2021

Barcode

No barcode data available

Springer Tumor Suppressor Par-4: Structural Features, Molecular Mechanisms and Function

New to our records — first sighting 22 days ago. We'll learn its rhythm.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development)

Tumor Suppressor Genes in Human Cancer (Cancer Drug Discovery and Development)

Targeted Therapies in Oncology

Mutant p53 and MDM2 in Cancer: 85 (Subcellular Biochemistry, 85)

Springer Mutant p53 and MDM2 in Cancer - Subcellular Biochemistry 85

Advancing Development of Synthetic Gene Regulators: With the Power of High-Throughput Sequencing in Chemical Biology (Springer Theses)

Targeted Therapies in Oncology

Advancing Development of Synthetic Gene Regulators: With the Power of High-Throughput Sequencing in Chemical Biology (Springer Theses)

Springer - The p53 Tumor Suppressor Pathway and Cancer 2

Precision Cancer Therapies, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice: 1 (Precision Cancer Therapies, Volume 1)

Environmental Factors, Genes, and the Development of Human Cancers

Springer - Environmental Factors, Genes, and Human Cancers

Cancer Cell Signaling: Targeting Signaling Pathways Toward Therapeutic Approaches to Cancer

PARP Inhibitors for Cancer Therapy (Cancer Drug Discovery and Development)

Cancer Cell Signaling: Targeting Signaling Pathways Toward Therapeutic Approaches to Cancer

Tumor Suppressor Genes: Volume 2: Regulation, Function, and Medicinal Applications: 223 (Methods in Molecular Biology, 223)

Epigenetic Regulation in Overcoming Chemoresistance (Volume 16) (Cancer Sensitizing Agents for Chemotherapy, Volume 16)

Hsp90 in Cancer: Beyond the Usual Suspects (Volume 129) (Advances in Cancer Research, Volume 129)

Cancer Drug Resistance: Overviews and Methods: 1395 (Methods in Molecular Biology, 1395)

MicroRNAs: Key Regulators of Oncogenesis

Cellular Cancer Markers: 12 (Contemporary Biomedicine, 12)

Cancer Epigenetics for Precision Medicine: Methods and Protocols: 1856 (Methods in Molecular Biology, 1856)

Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics

Psycho-Oncology: 197 (Recent Results in Cancer Research, 197)